Fatigue Pipeline Report - Drugs in Development, Worldwide, 2022 - ResearchAndMarkets.com Fatigue Pipeline Report - Drugs in Development, Worldwide, 2022

DUBLIN--(BUSINESS WIRE)--The "Fatigue Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

This pipeline guide provides an overview of the fatigue (central nervous system) pipeline landscape.

The guide provides comprehensive information on the therapeutics under development for fatigue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide describes the pharmacological actions of the therapeutics, its complete research & development history, and the latest news and press releases.

The pipeline guide also reviews key players involved in therapeutic development for fatigue, and features dormant and discontinued projects. The guide covers therapeutics under development by companies/universities/institutes, and the molecules developed by companies in: phase II, phase I, preclinical, and unknown stages are 4, 2, 3, and 2 respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of fatigue.
• The pipeline guide reviews pipeline therapeutics for fatigue by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise - product description, descriptive licensing & collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in fatigue therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates fatigue therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for fatigue.

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for fatigue.
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers & acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding fatigue’s pipeline depth and its focus of indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Topics Covered

Introduction

Report Coverage

Overview

Therapeutics Development

• Pipeline Overview
• Pipeline by Companies
• Products under Development by Companies

Therapeutics Assessment

• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Companies Involved in Therapeutics Development

• Aoxing Pharmaceutical Company Inc
• Bioprojet SCR
• Contero Therapeutics
• Dompe Farmaceutici S.p.A.
• Helsinn Group
• K-Pax Pharmaceuticals Inc.
• MetVital Inc.
• Primetime Life Sciences LLC
• Resolys Bio Inc.
• Sunny Pharmtech Inc.

Drug Profiles

• Anamorelin hydrochloride
• Anhydrous enol oxaloacetate
• Biologic for chronic pain and fatigue
• BP-1.3656B
• Caffeine
• CTDP-001
• KPAX-002
• Phenylbutyrate
• Pitolisant hydrochloride
• PLS-4
• Reparixin

Dormant Projects

For more information about this report visit https://www.researchandmarkets.com/r/19hckg

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900